

Hypertension in 2026

What's New, What's Changed, What Primary Care Needs to Know

Jim Liu, MD, FACC
Associate Professor - Clinical
Department of Internal Medicine
Division of Cardiovascular Medicine

The Ohio State University Wexner Medical Center

MedNet21
Center for Continuing Medical Education

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

Objectives

At the end of this session, participants will be able to:

- Describe key updates in the 2025 ACC/AHA hypertension guideline compared to 2017
- Apply risk-based treatment decisions using the PREVENT risk calculator
- Implement updated recommendations for diagnosis, treatment and follow-up

CLINICAL PRACTICE GUIDELINE

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines


Developed in Collaboration With and Endorsed by American Academy of Physician Associates; American Association of Nurse Practitioners; American College of Clinical Pharmacy; American College of Preventive Medicine; American Geriatrics Society; American Medical Association; American Society of Preventive Cardiology; Association of Black Cardiologists; National Medical Association; Preventive Cardiovascular Nurses Association; and the Society of General Internal Medicine.

Class (Strength) of Recommendation				Level (Quality) of Evidence			
Class	Interpretation	Benefit vs Risk	Suggested Wording	Level	Source of Evidence	Evidence Quality	Key Description
Class 1	Strong recommendation	Benefit >>> Risk	• Recommended / indicated • Should be performed • Clear benefit	Level A	Multiple RCTs / Meta-analyses	High	• Data from >1 randomized controlled trial • High-quality meta-analyses • Consistent, well-validated findings
Class 2a	Moderate recommendation	Benefit >> Risk	• Reasonable to perform • Likely beneficial • Preferred option	Level B-R	Randomized studies	Moderate	• Evidence from ≥1 RCT • Moderate-quality meta-analyses
Class 2b	Weak recommendation	Benefit ≥ Risk	• May be considered • Evidence less established	Level B-NR	Nonrandomized studies	Moderate	• Well-designed observational or registry studies • Nonrandomized data with consistent results
Class 3 (No Benefit)	Not useful	Benefit = Risk	• Not recommended • No proven benefit • Should not be performed	Level C-LD	Limited data	Low	• Studies with design or execution limitations • Small or heterogeneous datasets
Class 3 (Harm)	Harmful intervention	Risk > Benefit	• Harmful • Causes morbidity/mortality • Should not be performed	Level C-EO	Expert opinion	Very low	• Consensus based on clinical experience

Why care about hypertension?

- Hypertension is the most prevalent modifiable CVD risk factor
- Leading cause of death and disability worldwide

Figure 1. Prevalence of hypertension in adults age 18 and older, by sex and age: United States, August 2021–August 2023




SOURCE: National Center for Health Statistics, National Health and Nutrition Examination Survey, August 2021–August 2023.

Why care about hypertension?


- Prevalence of HTN is increasing
- Nearly half of all American adults will develop HTN

Figure 1. Prevalence of hypertension in adults age 18 and older, by sex and age: United States, August 2021–August 2023




SOURCE: National Center for Health Statistics, National Health and Nutrition Examination Survey, August 2021–August 2023.

High Blood Pressure Prevalence (%), 2021 Adults, Ages 18+, by County




Health Problems Caused by High Blood Pressure



Why care about hypertension?


- Cardiovascular disease
- Stroke
- Kidney disease
- Dementia



Illustrative re-creation of published ischemic heart disease mortality-blood pressure relationships; values digitized and approximated from original figures for presentation purposes

Levinson S, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. (The Lancet 2002;360:1903-13).

Cumulative Cardiovascular Risk over Time



Illustrative re-creation of published cumulative incidence curves; values digitized and approximated from original figures for presentation purposes

Vasan RS, et al. Impact of high-normal blood pressure on risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.


Why care about hypertension?

\$131 Billion


Annual cost to U.S. healthcare spending

Hypertension treatment and control

Figure 5. Prevalence of hypertension awareness, treatment, and control among adults age 18 and older with hypertension: United States, 2017-March 2020 and August 2021-August 2023



Source: NHANES 2017-2020 and August 2021-August 2023; NCHS Data Brief No. 511 (CDC)



Definition of Hypertension

Unchanged from 2017 guidelines

	Systolic BP		Diastolic BP
Normal BP	<120 mmHg	And	<80 mmHg
Elevated BP	120-129 mmHg	And	<80 mmHg
Hypertension			
Stage 1	130-139 mmHg	Or	80-89 mmHg
Stage 2	≥140 mmHg	Or	≥90 mmHg

BP is based on **average of ≥2 careful readings** obtained on **≥2 occasions**

Diagnosis

- Accurate office BP remains important
- Out-of-office BP confirmation is emphasized

Class 1	When diagnosing and managing high BP in adults, standardized methods are recommended for the accurate measurement
Class 2a	When measuring in-office BP, it is reasonable to use an automated device over the auscultatory method
Class 1	Out-of-office BP measurements by either APBM or HBPM are recommended to confirm hypertension
Class 1	HBPM is recommended for monitoring the titration of BP-lowering medication

White-coat and Masked Hypertension

	Healthcare setting BP	Home BP
Normotensive	No hypertension	No hypertension
Sustained hypertension	Hypertension	Hypertension
White coat hypertension	Hypertension	No hypertension
Masked hypertension	No hypertension	Hypertension

- Still important to assess for white-coat and masked htn
- White coat HTN has no significant increased risk of CVD
- White coat effect is NOT associated with increased CVD event and mortality.


White-coat and Masked Hypertension

Class 2a	In adults with untreated office SBP \geq 130 mmHg or DBP \geq 80 mmHg, and without office SBP \geq 160 mmHg or DBP \geq 100 mmHg, it is reasonable to exclude white-coat hypertension using out-of-office BP monitoring before a diagnosis of hypertension is made.
Class 2a	In adults with white-coat hypertension or masked hypertension, out-of-office BP monitoring is reasonable to exclude transition to a diagnosis of sustained hypertension
Class 2a	In adults with apparent treatment resistant hypertension on office BP, it is reasonable to exclude white-coat effect using out-of-office BP monitoring
Class 2a	In adults on BP medications with SBP \geq 130 mmHg or DBP \geq 80 mmHg and without office SBP \geq 160 mmHg or DBP \geq 100 mmHg, it is reasonable to exclude white-coat effect using out-of-office BP monitoring

- ### Proper Home Blood Pressure Monitoring
- Use a device that has been validated for accuracy (www.validatebp.org)
 - Use the correct cuff size for arm
 - Avoid smoking, caffeine, or exercise within 30 minutes before BP measurement
 - Place cuff on a bare arm above bend of elbow
 - Arm supported at level of heart
 - Sit in chair with feet on floor, legs uncrossed, back supported for at least 5 minutes
 - Do not talk, use phone, or watch TV while measuring
 - Take 2 readings 1 minute apart twice a day (total of 4 readings): 2 readings in the morning after emptying bladder and before medication and 2 readings at bedtime

	Effect on SBP
Acute alcohol use	-24 to +24 mmHg
Acute caffeine use	+3 to +14 mmHg
Acute nicotine use	+3 to +25 mmHg
Bladder distension	+4 to +33 mmHg
Legs crossed	+2 to +15 mmHg
Small BP cuff	+2 to +11 mmHg
No resting period	+4 to +11 mmHg
Talking while measuring	+4 to +19 mmHg
Unsupported arm or cuff too low	+4 to +23 mmHg

Kallioinen et. al. Sources of inaccuracy in the measurement of adult patients' resting blood pressure in clinical settings: a systematic review. Journal of Hypertension 2017, 35:421-441.

- ### Cuffless BP Monitors
- Numerous new personal and wearable devices for **estimating** BP
 - Rings, bracelets, watches, smartphones, smart glasses, chest patches, and toilet seat!
 - Several have FDA clearance
 - Cardiac sensor (ECG, impedance cardiogram) and pulsatility sensor (photoplethysmography, tonometry)
 - Requires periodic calibration with cuff BP measurement or demographic data
 - Lack of standardized validation process for wide variety of devices
- | | Recommendation for Cuffless BP Devices |
|----------------------|---|
| Class 3 (no benefit) | In adults, the use of cuffless BP devices is not recommended for the diagnosis or management of high BP |
- 

Evaluation

Class 1	For adults who are diagnosed with hypertension, laboratory tests (CBC, chemistry, lipid, A1c, TSH, UA, UACr) and 12-lead ECG should be performed to optimize management
Class 1	In adults with hypertension, screening for specific forms of secondary hypertension is recommended when clinical suspicion is present to increase rates of detection, diagnosis, and specific targeted therapy
Class 1	In adults with resistant hypertension, screening for primary aldosteronism is recommended regardless of whether hypokalemia is present to increase rates of detection, diagnosis, and specific targeted therapy.
Class 2a	In adults who have a positive screening test for a form of secondary hypertension, referral to a clinician who has expertise in that form of hypertension is reasonable for diagnostic confirmation and treatment

New

Upgraded from 2b

Secondary causes of hypertension

- Can be sole cause or contributing cause
- Estimated in 5-25% of all hypertension, higher in resistant hypertension.

Common causes	Uncommon causes
Renal parenchymal disease (CKD, urinary obstruction): 14%	Pheochromocytoma: <0.6% in all HTN, up to 4% in RH
Renovascular disease (atherosclerosis, FMD): 0.1-5%	Cushing's syndrome: <0.1%
Primary aldosteronism : 5-25%	Hypo and hyperthyroidism: <1%
OSA : 25-50%	Aortic coarctation: 0.1%
Drug or alcohol induced : 2-20%	Hyperparathyroidism, acromegaly, congenital adrenal hyperplasia: rare

When to consider secondary causes?

- Resistant hypertension
- Abrupt onset hypertension
- Exacerbation of previously controlled hypertension
- Onset of hypertension at <30 yo
- End organ damage disproportionate to htn duration/severity
- Accelerated/malignant hypertension
- Onset of diastolic hypertension in older adults (>65yo)
- Signs or symptoms suggestive of a specific cause
 - Unprovoked or excessive hypokalemia
 - Insomnia or daytime sleepiness
 - Concomitant adrenal nodule

	Signs and symptoms	Screening tests	Additional tests
Renovascular	Abrupt onset or worsening htn; labile htn; flash pulm edema	Renal duplex, MRA, CTA	Renal artery angiography
Aldosteronism	Hypokalemia	Plasma aldosterone/renin ratio	Sodium loading test, adrenal CT, adrenal vein sampling
OSA	Snoring, daytime fatigue	Overnight oximetry, Epworth score	Polysomnography
Pheochromocytoma	Labile BP, "spells"	24hr urine metanephrines (low suspicion), plasma metanephrines (high suspicion)	CT or MRI of abdomen/pelvis
Cushing's	Rapid weight gain, cushinoid features, prox muscle weakness	Overnight dexamethasone suppression test	24hr urinary cortisol, midnight salivary cortisol
Coarctation	Htn in <30yo	Echo	CT or MRA

Medications and Substances that Elevate BP

Nonprescription drugs/substances

- Alcohol
- Caffeine
- NSAIDs
- Decongestants (phenylephrine, pseudoephedrine)
- Herbal supplements (Ma Huang, ephedra, St. John's wort)
- Black licorice
- Recreational drugs (bath salts, cocaine, methamphetamine)

Prescription drugs

- Amphetamines
- Antidepressants (SNRIs, TCAs, MAOIs)
- Atypical antipsychotics (risperidone, olanzapine)
- Immunosuppressants (cyclosporine)
- Oral contraceptives (estrogen containing)
- Systemic corticosteroids
- Angiogenesis inhibitor (bevacizumab)
- Tyrosine kinase inhibitors
- Withdrawal of central-acting sympatholytic drugs (clonidine, tizanidine)

Primary Aldosteronism

- Inappropriate production of aldosterone
 - Intravascular volume expansion
 - Sodium retention
 - Potassium excretion
- Hypokalemia present in 9-37% of cases
- 2/3 due to bilateral adrenal hyperplasia and 1/3 due to unilateral aldosterone production
- 5-10% of patients with stage 1 Htn and 11-22% with stage 2 Htn
- PA is associated with increased risk of end organ damage (HF, stroke, CAD, AF, CKD) compared with primary hypertension
- Treated with MRA (spironolactone or eplerenone) or adrenalectomy

Primary Aldosteronism

Class 1	In adults with hypertension, screening for primary aldosteronism is recommended in the presence of any of the following conditions: resistant hypertension (regardless of whether hypokalemia is present), hypokalemia (spontaneous or diuretic induced), OSA, incidental adrenal mass, family history of early-onset hypertension, or stroke at young age (<40y)
Class 2b	In adults with stage 2 hypertension, screening for primary aldosteronism may be considered to increase rates of detection, diagnosis, and specific targeted therapy.
Class 1	Use of plasma aldosterone, renin activity, and the plasma aldosterone to renin activity ratio is recommended for initial screening.
Class 1	In adults with positive screening test or continued suspicion for PA based on suppressed renin, referral to hypertension specialist or endocrinologist is recommended for further evaluation and treatment

1. Suppressed renin
2. PAC >10 ng/dL
3. Aldosterone renin ratio >30 (using ng/dL for PAC and ng/mL/h for PRA)

New

Primary Aldosteronism

Class 1	In adults with an indication for screening for primary aldosteronism, it is recommended to continue most antihypertensive medications (other than MRAs) prior to initial screening to minimize barriers to or delays in screening.
---------	--

New

	EFFECT ON ALDOSTERONE	EFFECT ON RENIN	EFFECT ON ARR
β-adrenergic blockers	↓	↓↓	↑ (FP)
Central α ₂ -agonists	↓	↓↓	↑ (FP)
NSAIDs	↓	↓↓	↑ (FP)
K ⁺ -wasting diuretics	↓ / ↑	↑↑	↓ (FN)
K ⁺ -sparing diuretics	↑	↑↑	↓ (FN)
ACE inhibitors	↓	↑↑	↓ (FN)
ARBs	↓	↑↑	↓ (FN)
Dihydropyridine CCB	→ OF ↓	↑	↓ (FN)
Renin inhibitors	↓	↓	↑ (FP)

BP Management: Lifestyle and Psychosocial

- Weight
- Diet and nutrients
- Alcohol
- Physical activity
- Stress reduction


Weight

Class 1	In adults who have overweight or obesity, weight loss is recommended with a goal of at least 5% of body weight reduction to prevent or treat elevated BP and hypertension.
---------	---

- BP reduction occurs with weight loss, regardless of mechanism (lifestyle, cognitive behavioral therapy, medication, surgery)
- Expect 1mmHg reduction in BP for every 1 kg of weight loss

Weight

Class 2b	In adults with hypertension who also have overweight or obesity with a BMI ≥ 27 kg/m ² , incretin mimetics (e.g. GLP-1 receptor agonists) when used for weight management may be effective as an adjunct to lower BP.
Class 2b	In adults with hypertension who also have obesity with a BMI ≥ 35 kg/m ² , bariatric surgery (when considered for weight loss) in combination with behavioral interventions and antihypertensive therapies may be effective at lowering BP.



- Use of GLP-1 receptor agonists reduce BP in patients with excess weight and without diabetes.
- Roux-en-Y gastric bypass is effective at improving BP


Diet

Class I	In adults with or without hypertension , a heart-healthy eating pattern, such as DASH eating plan, is recommended to prevent or treat elevated BP and hypertension.
Class I	In adults with or without hypertension, reduction of dietary sodium intake is recommended to $< 2,300$ mg/day moving toward an ideal limit of $< 1,500$ mg/day
Class 2a	In adults with or without hypertension, potassium-based salt substitutes can be useful to prevent or treat elevated BP and hypertension, particularly for patients in whom salt intake is related mostly to food preparation or flavoring at home, except in the presence of CKD or use of drugs that reduce potassium excretion.
Class I	In adults with elevated BP or hypertension, moderate potassium supplementation (< 80 mEq/day), ideally from dietary sources, is recommended to prevent or treat elevated BP and hypertension, except in the presence of CKD or use of drugs that reduce potassium excretion.



Alcohol

Class 1	Adults with or without hypertension who currently consume alcohol should be advised to pursue a recommended goal of abstinence , or at least to reduce alcohol intake to ≤ 1 drink/day for women and ≤ 2 drinks/day for men to prevent and treat elevated BP and hypertension.
---------	---



Greater BP reduction in those with higher baseline alcohol intake

Physical Activity

Class 1	In adults with or without hypertension, increasing physical activity, through a structured exercise program that includes aerobic exercise and/or resistance training, is recommended to prevent or treat elevated BP and hypertension.
---------	---

- **Aerobic exercise** (endurance activities, jogging, walking): reduces SBP 4-7, more in patients with hypertension
- **Dynamic resistance** (weightlifting): more modest effect on BP vs aerobic exercise, avg SBP reduction 3 mmHg
- **Static/isometric resistance training** (handgrip, planks, wall sit): may have largest effect, avg SBP reduction 8 mmHg.

Stress Reduction

Class 2b	In adults with or without hypertension, stress reduction through transcendental meditation may be reasonable to prevent or treat elevated BP and hypertension, as an adjunct to lifestyle or medication.
Class 2b	In adults with or without hypertension, other forms of stress management, such as breathing control techniques or yoga, may be reasonable to prevent or treat elevated BP and hypertension, as an adjunct to lifestyle or medication interventions.



- Meditation can lower SBP/DBP by 5/2 mmHg
- Breathing control interventions lower SBP/DBP by 5/3 mmHg

Intervention	Target / Biomarker	Key Recommendation	SBP Reduction (mm Hg)	
			With Hypertension	Without Hypertension
Weight loss	Body weight or BMI	Aim for sustained 25% weight loss , ~1 mm Hg SBP reduction per kg lost	-6 to -8	-3 to -5
Heart-healthy diet (DASH)	Diet pattern	Fruits, vegetables, whole grains, low-fat dairy; reduced saturated fat	-5 to -8	-3 to -7
Reduced sodium intake	Dietary sodium	Ideal: <1500 mg/day ; optimal goal: <2300 mg/day	-6 to -8	-1 to -4
Salt substitute use	Sodium / potassium balance	Replace regular salt with potassium-enriched salt (~65-75% KCl)	-5 to -7	-5
Increased potassium intake	Dietary potassium	3500-5000 mg/day from food (preferably) or supplements	-6	-3 to -6
Reduced alcohol intake	Alcohol consumption	≤ 2 drinks/day (men); ≤ 1 drink/day (women)	-4 to -6	-3
Aerobic exercise	Physical activity	90-150 min/week (e.g., brisk walking)	-4 to -8	-2 to -7
Dynamic resistance exercise	Muscle strength	90-150 min/week , moderate intensity	-2 to -7	-2 to -5
Isometric resistance exercise	Muscle tension	Handgrip: 4 x 2 min , 30-40% max effort	-5 to -10	-4 to -6
Meditation	Stress response	Transcendental meditation, 20 min twice daily	-5 to -7	-5
Breathing control	Respiratory rate	Device-guided slow breathing (<10 breaths/min, 15 min/day)	-5	-5

Pharmacologic Treatment


Class 1	In all adults with hypertension, initiation of medications to lower BP is recommended when average SBP ≥140 mmHg or DBP ≥90 mmHg to reduce the risk of cardiovascular events and total mortality.	
Class 1	In adults with hypertension and clinical CVD , initiation of medications to lower BP is recommended when average SBP ≥130 mmHg or DBP ≥80 mmHg to reduce the risk of cardiovascular events and total mortality.	← Updated
Class 1	In adults with hypertension without clinical CVD but with diabetes or CKD or estimated 10yr CVD risk ≥7.5% based on PREVENT , initiation of medications to lower BP is recommended when average SBP ≥130 mmHg or DBP ≥80 mmHg to reduce the risk of cardiovascular events and total mortality.	← Updated
Class 1	In adults with hypertension without clinical CVD and with estimated 10yr risk <7.5% , initiation of medications to lower BP is recommended if average SBP ≥130 mmHg or DBP ≥80 mmHg after a 3-to-6-month trial of lifestyle intervention.	

- ### PREVENT Equations
- Predicting Risk of CVD EVENTS
 - Estimates 10yr and 30yr risk of total CVD (MI, stroke, and HF)
 - Valid for ages 30-79
 - Derived from more contemporary data 6.5 million individuals with more diverse population
 - Same parameters as 2013 ASCVD risk calculator: sex, age, SBP, total chol, HDL chol, diabetes, smoking, lipid-lowering medications, anti-hypertensive medications
 - New parameters: eGFR, BMI, Urine albumin-creatinine ratio, A1c, Zip code

PREVENT Equations

Class 1	In adults with hypertension without clinical CVD but with diabetes or CKD or estimated 10yr CVD risk ≥7.5% based on PREVENT , initiation of medications to lower BP is recommended when average SBP ≥130 mmHg or DBP ≥80 mmHg to reduce the risk of cardiovascular events and total mortality.
---------	--

10yr estimated CVD risk ≥7.5% with PREVENT ≈ 10yr estimated ASCVD risk ≥10% with PCE





Medication selection

First line agents	
Class 1	For adults initiating antihypertensive drug therapy: thiazide diuretics, DHP calcium channel blockers, and ACE-I or ARB are recommended as first line agents.
Alternative agents	
Beta-blockers, combined beta/alpha blockers (carvedilol, labetalol)	Central α2-agonist (clonidine)
Non-DHP CCB (diltiazem, verapamil)	Alpha-1 blockers (doxazosin, prazosin)
Loop diuretics (furosemide, torsemide, bumetanide)	Direct vasodilators (hydralazine, minoxidil)
Potassium sparing diuretics (amilofride, triamterene)	Direct renin inhibitor (aliskiren)
MRAs (spironolactone, eplerenone)	Dual endothelin receptor antagonist (aprocitanan)

Medication selection

Initial combination drug therapy	
Class 1	In adults with stage 2 hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg), initiation of antihypertensive drug therapy with 2 first-line agents of different classes, ideally in a single-pill combination (SPC), is recommended to improve BP control and adherence.
Class 2a	In adults with stage 1 hypertension (SBP 130-139 mmHg and DBP 80-90 mmHg), initiation with a single first-line antihypertensive drug is reasonable with dose titration and sequential addition of other agents as needed.

- Most patients with hypertension require ≥2 meds
- Combination therapy is more effective in lowering BP than stepwise approach
- Complementary mechanisms
- Lower risk of side effects



Medication selection

Medication adherence strategies	
Class 1	The use of SPC to reduce pill burden rather than taking separate pills is effective to improve medication adherence.
Class 1	Choose medications dosed once daily rather than multiple times daily to improve medication adherence.

Antihypertensive Medication SPCs
ACE-I/ARB + thiazide diuretic
Potassium-sparing diuretic + thiazide diuretic
ACE-I/ARB + CCB
MRA + thiazide diuretic
ARB + CCB + thiazide diuretic
ARB + BB
BB + thiazide diuretic



BP Goal

Class 1	In adults with hypertension who are at increased risk for CVD (10yr CVD risk ≥7.5% by PREVENT), an SBP goal of <130 mmHg, with encouragement to achieve <120 mmHg, and DBP <80 mmHg is recommended.
Class 2b	In adults with hypertension who are not at increased risk for CVD (10yr CVD risk <7.5% by PREVENT), an SBP goal of <130 mmHg, with encouragement to achieve <120 mmHg, and DBP <80 mmHg is reasonable.



BP Goal and Comorbidities

	Comorbidity	BP Goal
Class I	Diabetes	<ul style="list-style-type: none"> • SBP <130 mmHg, with encouragement to achieve SBP <120 mmHg • DBP <80 mmHg
Class I	CKD (eGFR <60) or albuminuria (≥30 mg albumin/g creatinine)	<ul style="list-style-type: none"> • SBP <130 mmHg
Class I	Heart failure	<ul style="list-style-type: none"> • SBP <130 mmHg • DBP <80 mmHg
Class I	Stroke, TIA, or ICH	<ul style="list-style-type: none"> • SBP <130 mmHg • DBP <80 mmHg


Special populations

	Diabetes with CKD
Class 1	In adults with diabetes and hypertension, ACEi or ARB are recommended in the presence of CKD (eGFR <60 or albuminuria ≥30 mg/g and should be considered when mild albuminuria (<30 mg/g) is present to delay progression of diabetic kidney disease.
	CKD
Class 1	For adults with hypertension and CKD (eGFR <60 with albuminuria ≥30 mg/g), ACEi or ARB is recommended to decrease CVD and delay progression of kidney disease.



Dementia


Class 1	In adults with hypertension, a goal of SBP <130 mmHg is recommended to prevent mild cognitive impairment and dementia
---------	---



- Hypertension is the primary risk factor for small-vessel ischemic disease and cortical white matter abnormalities
- Often co-exists in patients with Alzheimer's dementia
- BP control helps reduce Alzheimer disease

Follow-up

- Normal BP (<120/80 mmHg): reassess in 1y (class I)
- Elevated BP (120-129/<80 mmHg): reassess in 3-6 mo (class I)
- Stage 1 or 2 hypertension:
 - Reassess 1 mo after starting or intensifying BP meds (class I)
 - Reassess 3-6 mo after BP goal met (class I)



Resistant Hypertension

- Uncontrolled resistant htn: BP above goal despite treatment with 3 medications, including a diuretic at maximally tolerated doses.
- Controlled resistant htn: BP at goal but requiring ≥ 4 meds
- 9-20% of adults with htn in US
- Increased risk of MI, stroke, ESRD, cardiovascular death compared to hypertension without resistance

Resistant Hypertension

Class 1	In adults with resistant hypertension, a more detailed evaluation for secondary causes, to include careful review of all medications and removal of those with interfering effects on BP, is beneficial for lowering BP and simplifying treatment	← New
Class 1	In adults with uncontrolled resistant hypertension despite optimal treatment with first-line agents and with eGFR >45 , addition of a MRA is recommended to control BP.	← New
Class 2a	In adults with uncontrolled resistant hypertension who cannot tolerate or have contraindications to MRA, the addition of one of the following agents or classes is reasonable to control BP: BBs, alpha-blockers, central sympatholytic drugs, dual endothelin receptor antagonists, direct vasodilators, amiloride.	← New

Think of secondary causes, contributing meds




Use spironolactone as 4th agent

- ### Resistant Hypertension
1. Confirm resistant hypertension
 2. Optimize 3 first-line drug regimen
 3. Exclude pseudoresistance: accurate BP measurement, assess for med adherence, exclude white-coat effect
 4. Address lifestyle factors
 5. Minimize interfering substances
 6. Screen for secondary causes
 7. Pharmacologic therapy:
 - Switch thiazide to chlorthalidone (\downarrow SBP 7-8 mmHg)
 - Add spironolactone or eplerenone if eGFR ≥ 45
 - Add agents with different mechanisms of action

Renal Denervation

- FDA approval November 2023
- Radiofrequency or ultrasound energy to ablate efferent and afferent renal nerves
- No significant procedural risks beyond typical femoral arterial access risks
- Contraindications: pregnancy, stented renal artery, renal artery aneurysm, significant renal artery stenosis, FMD, kidney tumors
- ~5 mmHg improvement in SBP
- 60-70% of patients experienced meaningful improvement in SBP

Renal Denervation

Class 2b	In carefully selected patients with systolic and diastolic hypertension (SBP \geq 140 mmHg and DBP \geq 90 mmHg) and eGFR \geq 40 who have resistant hypertension despite optimal treatment or intolerable side effects to additional antihypertensive drug therapy, renal denervation may be reasonable as an adjunct treatment to BP medications and lifestyle modification to reduce BP.	
Class 1	All patients with hypertension who are being considered for RDN should be evaluated by a multidisciplinary team with expertise in resistant hypertension and RDN.	
Class 1	For patients with hypertension for whom RDN is contemplated, the benefits of lowering BP with potential procedural risks compared with continuing medical therapy should be discussed as part of a shared decision-making process.	

Patient selection is important

Not meant to be a curative therapy or replacement for meds

What else?

- Acute intracranial hemorrhage
- Acute stroke
- Hypertension and pregnancy
- Hypertensive emergency and severe hypertension
- Patients scheduled for surgical procedures
- Complications of management (sexual dysfunction, orthostatic hypotension)

Take-away points

- Screen for primary aldosteronism
- Use PREVENT to estimate CVD risk
- Start 2 antihypertensive agents for stage 2 hypertension
- Use single pill combinations when possible
- BP goal <130/80, with encouragement of SBP <120 mmHg
- Guidelines are just guidelines!